Cargando…
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab
Anti-PD-L1 antibodies benefit many cancer patients, even those with “non-inflamed tumor”. Determining which patients will benefit remains an important clinical goal. In a non-inflamed tumor mouse model, we found that PD-L1 was highly expressed on antigen-presenting cells (APCs) especially on CD103(+...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260627/ https://www.ncbi.nlm.nih.gov/pubmed/34230534 http://dx.doi.org/10.1038/s41598-021-93113-y |